Adjusted Hazard Ratios for Predictors of Initiation of Antidepressants within 6 months of Bereavement.

a<p>Hazard ratios adjusted for all determinants in table, UK Region and Year.</p>b<p>Comparing Association in Bereaved and Non-Bereaved Groups.</p>c<p>Quintiles of annual practice prescribing to non-bereaved couples (% of patients in receipt of this drug class).</p>*<p>Full data on non-bereaved analysis is presented in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0077734#pone.0077734.s001" target="_blank">table S1</a>.</p

Probability of Initiation (%) of Psychotropic Drugs in the Year after Bereavement in Bereaved (B) and Non Bereaved (NB) Patients.

<p>Initiation probabilities during the first year after bereavement are derived from Kaplan Meier estimates and divided into the following periods Light Grey: 6–12 months Medium Grey: 2–6 months Dark Grey: 0–2 months.</p

Psychotropic Medication Initiation in the First Year after Bereavement Compared to Non-Bereaved Patients.

a<p>Person months at risk (% Initiation per month).</p>b<p>Excludes low dose amitriptyline.</p

Proportion of Patients in Receipt of Psychotropic Medication in the Year Before and After Bereavement.

<p>Blue: All Bereaved (n = 29,548) Green: All Non-Bereaved (n = 80,471) Red: Bereaved without psychotropic medication in year before bereavement (n = 21,122) Purple: Non-Bereaved without psychotropic medication in year before bereavement (n = 59,280) Daily percentages are based on a denominator of patients still registered on that day.</p

One Year Continuation of Psychotropic Medication Initiated in the First Two Months after Bereavement.

*<p>Alive and registered with practice on first anniversary of bereavement date.</p>†<p>Received same class of medication within 90 days of anniversary of bereavement.</p

Additional file 1: of Evaluation of reliability and validity of the General Practice Physical Activity Questionnaire (GPPAQ) in 60–74 year old primary care patients

General practice physical activity questionnaire. (JPEG 87 kb

Baseline characteristics of 298 randomised participants.

<p>^aNational quintiles of Index of Multiple Deprivation rank [<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001783#pmed.1001783.ref021" target="_blank">21</a>].</p><p>^bFull references for general health, chronic disease score, limiting long-standing illness, self-reported pain, Falls Risk Assessment Tool (FRAT), Geriatric Depression Score (GDS-15), FEAR anxiety score, Townsend Disability Score, Self-Efficacy Score, difficulty in paying bills, are given in the trial protocol [<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001783#pmed.1001783.ref013" target="_blank">13</a>].</p><p>^cFor fat mass, waist circumference, and all accelerometry data, numbers presented are mean (standard deviation [SD]).</p><p>Baseline characteristics of 298 randomised participants.</p

PACE-UP and PACE-Lift studies.

<p><b>Effect estimates and 95% confidence intervals for change in (a) average daily steps and (b) total weekly minutes of MVPA in bouts at 3 months, 12 months, and 3 years (PACE-UP) and 4 years (PACE-Lift).</b> Effect sizes, 95% confidence intervals, and <i>p-</i>values were obtained from multilevel linear regression models (see <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1002526#sec009" target="_blank">Methods</a>). 3 months: <i>p</i> < 0.001 for all PACE-UP and PACE-Lift steps and MVPA intervention effects. 12 months: <i>p</i> < 0.001 for PACE-UP steps and PACE-UP MVPA; <i>p</i> = 0.02 for PACE-Lift steps and <i>p</i> < 0.001 for PACE-Lift MVPA. 3 years: <i>p</i> < 0.01 for PACE-UP steps and PACE-UP MVPA postal group; <i>p</i> = 0.03 for PACE-UP MVPA nurse group. 4 years: <i>p</i> = 0.17 for PACE-Lift steps and <i>p</i> = 0.02 for PACE-Lift MVPA. MVPA, moderate-to-vigorous physical activity; PACE-Lift, Pedometer Accelerometer Consultation Evaluation-Lift; PACE-UP, Pedometer And Consultation Evaluation-UP.</p

PACE-Lift CONSORT diagram.

<p>PACE-Lift CONSORT diagram.</p

Other outcome measures.

<p>^<b>a</b>The treatment effect is the difference between groups (intervention-control) in change from baseline at 3 months and 12 months. The differences at 3 and 12 months are adjusted for baseline measure, practice, age, gender, and month of baseline accelerometry in a multi-level model with household as a random effect.</p><p>^<b>b</b>Fat mass was missing for six and three participants in the control group and for five and seven participants in the intervention group at baseline and 3 months, respectively.</p><p>^<b>c</b>Geriatric depression scores, fear anxiety scores, and self-reported pain were missing for varying numbers of participants (maximum 15) at each time-point.</p><p>Other outcome measures.</p